Vaccines to protect against Bundibugyo virus disease are being developed urgently, in support of the nationally led response to the current outbreak in the Democratic Republic of the Congo. For safe and effective vaccines to reach the people who need them as quickly as possible, planning for post-trial access must happen alongside research and development, not after it. That means planning in advance across the access spectrum, from the regulatory and policy pathways that enable access through to manufacturing, financing and delivery considerations.
To support this planning, the interim Medical Countermeasures network (i-MCM-net) within the Vaccine Pillar of the Continental Incident Management Support Team has developed a Vaccine Access Roadmap. The document was co-developed by the Vaccine Pillar partners: Africa CDC, CEPI, Gavi, WHO (HQ and AFRO) and UNICEF, with multiple other stakeholders informing its development.
The Roadmap maps the pathway to equitable access, identifies the known roles & responsibilities across the ecosystem, and highlights the most critical access priorities. Its aim is to give all vaccine response partners a shared approach to access. That way, R&D progress can be translated rapidly into accessible, suitable and implementable vaccination in Bundibugyo virus-affected communities.
The Roadmap makes the following recommendations for governments, vaccine response partners and funders to accelerate access to Bundibugyo virus vaccines:
- Sustain clinical trial momentum and include special populations so they are not excluded from timely access.
- Continue to prioritise risk communication and community engagement and integrate social and behavioural science into trials and beyond.
- Prepare urgently for any expanded access or compassionate use of vaccines.
- Streamline regulatory pathways and outline sequencing and conditions for national and global regulatory authorisations.
- Ensure that product liability and indemnification (I&L) is not a barrier to across different regulatory scenarios.
- Incorporate programmatic suitability considerations into vaccine funding decisions.
- Define and communicate assumptions around an allocation mechanism for potential future vaccines should the outbreak expand beyond the DRC.
- Ensure country-level operational readiness to authorize, receive, deliver and administer vaccine doses.
- Integrate special access approaches for humanitarian populations of concern.
- Continue efforts to improve country-level active surveillance and community listening systems.
A high-level summary in English and French and the full roadmap in English and French are available to download.
Feedback from stakeholders is welcome at [email protected]




